Drawing for MOSAICS

USPTO serial 78939686

MOSAICS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LEVINE, HOWARD B
Law office
TMO LAW OFFICE 115 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with MOSAICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jake Feldman

Jake Feldman Johnson & Johnson Law Department8 One Johnson & Johnson PlazaNew Brunswick, NJ 08933UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
003Non-medicated mouth rinses and non-medicated breath fresheners; mouthwash; non-medicated oral dissolving breath freshener strips; effervescent denture cleanser; toothpaste; skin soap; hand and body lotion; skin cream; hand cream; cold cream; all purpose cotton swabs for personal use; lip balmACTIVE—
005Therapeutic ophthalmic preparations; eye drops; laxatives; antacids for the treatment of gastrointestinal disorders; antacid mints; antidiarrheal preparations; pharmaceutical preparations for the treatment of diarrhea, constipation, and abdominal discomfort; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for human use being gastric fluid inhibitors; pharmaceutical preparations, namely, a histamine H2-receptor antagonist for the treatment of upper respiratory conditions; pharmaceutical preparation for the alleviation of ulcers, treatment and/or alleviation of heartburn and other gastro-intestinal disorders; medicated mouth rinses and breath fresheners; antiseptic mouthwash; denture adhesive cream; antiseptic throat lozenges; antiseptic for personal hygiene; anti-plaque mouth rinse; dental plaque remover; preparation for relief of anorectal discomfort; ointment for the treatment of minor rectal inflammation and minor skin irritations; hydrocortisone ointment; hemorrhoidal suppository; hemorrhoid relief preparation; medicated personal cleansers; medically treated hemorrhoidal pads, ointment and witch hazel cream; athlete's foot preparation; anti-fungal preparation for medical use; medicated skin lotion; anti-itch preparation; medicated hand lotion; topical analgesic preparations; medical compound in the form of ointments and creams for treatment of wounds, skin abrasions, bruises, chapped skin, bedsores, sore feet, burns, scalds, sunburns, wind bite, diaper rash and rectal irritation for use in dermatology and pediatrics; mixture of antibiotics for use in the treatment of general and local bacterial and virus infections; pharmaceutical preparations for treating dermatosis; medicated skin lotion for the relief of itch caused by insect bites, eczema, sunburn and poison ivy; mixture of antibiotics for use in the treatment of general and local bacterial and virus infections; medicated lip balm for treatment of cold sores and dry or chapped lips; pharmaceutical preparation, namely, a topical dermatological for treatment of alopecia; vitamins; adhesive bandages; pharmaceutical preparation for temporary relief of nasal congestion; sinus and allergy preparations containing antihistamines, analgesics and decongestant; pharmaceutical preparations containing diphenhydramine hydrochloride for the relief of hay fever symptoms, itching skin, hives, motion sickness, cough, and sleeping difficulty; medicinal pharmaceutical preparations, namely, allergy prevention cromolyn sodium based allergy prevention nasal spray; cough syrup; sleep aid preparation, namely, sleeping pills; allergy prevention nasal spray; pharmaceutical preparations for the relief of symptoms affecting any part of the respiratory tract; pharmaceutical preparations for the relief and prevention of upper respiratory and sinus symptoms and infections; sinus headache tablets; sinus medication; pharmaceutical preparations for use in connection with upper respiratory conditions; medicinal preparation intended for use as a sympathomimetic cough medication, decongestant and antihistamine; allergy and sinus medications; air freshener; refills for air fresheners; analgesic/antispasmodic for relief of menstrual discomfort; pain relieving adhesive skin patches; sleep aids for the treatment of insomnia; cough and throat drops; analgesics; anti-inflammatory pharmaceutical preparations; analgesic preparations for the treatment of headaches, backaches, back pain, menstrual pain, and muscle pain; pharmaceutical preparations for the treatment of urological conditions and overactive bladder; dimenhydrinate tablets useful in the prevention and treatment of motion sickness, nausea and vomiting; histamine antagonist; liquid fiber composition for the treatment of gastro-intestinal disorders; pharmaceutical substances, namely, miconazole nitrate antimicrobial cream; anti-allergic solution for the prevention and treatment of allergic rhinitis; pediatric cold preparations; allergy relief medicationACTIVE—
016Facial tissuesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Sep 28, 2010MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Sep 28, 2010ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 2, 2010CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 2, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 3, 2010RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Aug 3, 2009RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Feb 2, 2009RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 31, 2008RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 28, 2008RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 16, 2008ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 16, 2008REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 26, 2007CNSLLETTER OF SUSPENSION MAILED—
Jul 25, 2007CNSLSUSPENSION LETTER WRITTEN—
Jun 18, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Jun 18, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 18, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 18, 2007ALIEASSIGNED TO LIE—
Jun 1, 2007MAILPAPER RECEIVED—
May 17, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 17, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 29, 2007TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 12, 2007TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 7, 2007ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Nov 20, 2006CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 11, 2006DOCKASSIGNED TO EXAMINER—
Aug 3, 2006MDSCNOTICE OF DESIGN SEARCH CODE MAILED—
Aug 2, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance